Abstract
Introduction: Dry weight management in dialysis patients is crucial but often subjective, primarily based on symptoms. Due to continuous fluid removal in peritoneal dialysis (PD) and intermittent ultrafiltration in hemodialysis (HD), symptom-based assessments may be biased, leading to varying results. Surprisingly, no direct comparison of dry weight changes between PD and HD has been conducted. This study aimed to evaluate the impact of transitioning from PD to HD on body weight and related clinical parameters. Methods: This retrospective cohort study included 127 stable PD patients who transitioned to HD. Changes in body weight, echocardiographic parameters, albumin, and hemoglobin levels were analyzed over a 1-year period post-transition. Results: The mean patient age was 57.1 ± 15.5 years, with an average PD vintage of 5.8 ± 4.9 years. Most patients had hypertension. After transitioning to HD, body weight decreased significantly, with a reduction of −2.8 kg at 1 month, −5.3 kg at 3 months, and −7.5 kg 1 year post-transition. Echocardiographic parameters showed no significant changes. However, serum albumin and hemoglobin levels increased slightly but significantly after the transition, and the number of antihypertensive medications was also reduced. Conclusion: The transition from PD to HD results in significant reductions in body weight. These findings underscore the often-overlooked issue of fluid overload in PD patients and its potential impact on patient outcomes.
Journal Section:
Patient-oriented, Translational Research
References
1.
2.
Zoccali
C
, Mallamaci
F
. Mapping progress in reducing cardiovascular risk with kidney disease: managing volume overload
. Clin J Am Soc Nephrol
. 2018
;13
(9
):1432
–4
. 3.
Dekker
MJ
, Marcelli
D
, Canaud
BJ
, Carioni
P
, Wang
Y
, Grassmann
A
, et al. Impact of fluid status and inflammation and their interaction on survival: a study in an international hemodialysis patient cohort
. Kidney Int
. 2017
;91
(5
):1214
–23
. 4.
Zoccali
C
, Moissl
U
, Chazot
C
, Mallamaci
F
, Tripepi
G
, Arkossy
O
, et al. Chronic fluid overload and mortality in ESRD
. J Am Soc Nephrol
. 2017
;28
(8
):2491
–7
. 5.
Gunal
AI
. How to determine ‘dry weight
. Kidney Int Suppl
. 2013
;3
(4
):377
–9
. 6.
Loutradis
C
, Papadopoulos
CE
, Sachpekidis
V
, Ekart
R
, Krunic
B
, Karpetas
A
, et al. Lung ultrasound-guided dry weight assessment and echocardiographic measures in hypertensive hemodialysis patients: a randomized controlled study
. Am J Kidney Dis
. 2020
;75
(1
):11
–20
. 7.
Kim
HR
, Bae
HJ
, Jeon
JW
, Ham
YR
, Na
KR
, Lee
KW
, et al. A novel approach to dry weight adjustments for dialysis patients using machine learning
. PLoS One
. 2021
;16
(4
):e0250467
. 8.
Li
SY
, Chuang
CL
, Lin
CC
, Tsai
SH
, Chen
JY
. Peritoneal-membrane characteristics and hypervolemia management in peritoneal dialysis: a randomized control trial
. Membr
. 2021
;11
(10
):768
. 9.
Hecking
M
, Madero
M
, Port
FK
, Schneditz
D
, Wabel
P
, Chazot
C
. Fluid volume management in hemodialysis: never give up
. Kidney Int
. 2023
;103
(1
):2
–5
. 10.
Tseng
CH
, Hu
YA
, Chen
YT
, Yu
WC
, Lin
CC
, Li
SY
. Beyond prevalence: significance and differential impact of echocardiographic abnormalities in dialysis patients
. J Nephrol
. 2024
;37
(5
):1261
–71
. 11.
Kooman
JP
, van der Sande
FM
, Leunissen
KM
. Wet or dry in dialysis--can new technologies help
. Semin Dial
. 2009
;22
(1
):9
–12
. 12.
Dou
Y
, Zhu
F
, Kotanko
P
. Assessment of extracellular fluid volume and fluid status in hemodialysis patients: current status and technical advances
. Semin Dial
. 2012
;25
(4
):377
–87
. 13.
Alexandrou
ME
, Theodorakopoulou
MP
, Sarafidis
PA
. Lung ultrasound as a tool to evaluate fluid accumulation in dialysis patients
. Kidney Blood Press Res
. 2022
;47
(3
):163
–76
. 14.
Ohashi
Y
, Sakai
K
, Hase
H
, Joki
N
. Dry weight targeting: the art and science of conventional hemodialysis
. Semin Dial
. 2018
;31
(6
):551
–6
. 15.
Lang
RM
, Badano
LP
, Mor-Avi
V
, Afilalo
J
, Armstrong
A
, Ernande
L
, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
. J Am Soc Echocardiogr
. 2015
;16
(3
):233
–70
. 16.
Hickson
LJ
, Negrotto
SM
, Onuigbo
M
, Scott
CG
, Rule
AD
, Norby
SM
, et al. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis
. J Am Coll Cardiol
. 2016
;67
(10
):1173
–82
. 17.
Mitchell
C
, Rahko
PS
, Blauwet
LA
, Canaday
B
, Finstuen
JA
, Foster
MC
, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography
. J Am Soc Echocardiogr
. 2019
;32
(1
):1
–64
. 18.
Hung
SC
, Kuo
KL
, Peng
CH
, Wu
CH
, Lien
YC
, Wang
YC
, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease
. Kidney Int
. 2014
;85
(3
):703
–9
. 19.
Guo
Q
, Yi
C
, Li
J
, Wu
X
, Yang
X
, Yu
X
. Prevalence and risk factors of fluid overload in Southern Chinese continuous ambulatory peritoneal dialysis patients
. PLoS One
. 2013
;8
(1
):e53294
. 20.
Ng
JK
, Kwan
BC
, Chow
KM
, Pang
WF
, Cheng
PM
, Leung
CB
, et al. Asymptomatic fluid overload predicts survival and cardiovascular event in incident Chinese peritoneal dialysis patients
. PLoS One
. 2018
;13
(8
):e0202203
. 21.
Alexandrou
ME
, Balafa
O
, Sarafidis
P
. Assessment of hydration status in peritoneal dialysis patients: validity, prognostic value, strengths, and limitations of available techniques
. Am J Nephrol
. 2020
;51
(8
):589
–612
. 22.
Plum
J
, Schoenicke
G
, Kleophas
W
, Kulas
W
, Steffens
F
, Azem
A
, et al. Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods
. Nephrol Dial Transpl
. 2001
;16
(12
):2378
–85
. 23.
Yilmaz
Z
, Yildirim
Y
, Aydin
FY
, Aydin
E
, Kadiroglu
AK
, Yilmaz
ME
, et al. Evaluation of fluid status related parameters in hemodialysis and peritoneal dialysis patients: clinical usefulness of bioimpedance analysis
. Med Kaunas
. 2014
;50
(5
):269
–74
. 24.
United States Renal Data System(USRDS)2023 Annual Data Report
. [United States Renal Data System - USRDS - NIDDK].25.
Ortega
LM
, Materson
BJ
. Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment
. J Am Soc Hypertens
. 2011
;5
(3
):128
–36
. 26.
Rodriguez
HJ
, Domenici
R
, Diroll
A
, Goykhman
I
. Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line
. Kidney Int
. 2005
;68
(2
):854
–61
. 27.
Sinha
AD
, Light
RP
, Agarwal
R
. Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight
. Hypertension
. 2010
;55
(2
):305
–11
. 28.
Gilford
S
. Managing fluid control in the peritoneal dialysis population
. Clin J Am Soc Nephrol
. 2019
;14
(6
):783
–4
. 29.
Foley
RN
, Parfrey
PS
, Kent
GM
, Harnett
JD
, Murray
DC
, Barre
PE
. Long-term evolution of cardiomyopathy in dialysis patients
. Kidney Int
. 1998
;54
(5
):1720
–5
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
